Bal Pharma (Small Cap) Share Target 2026, 2027 To 2035
|
Bal Pharma Limited |
|||
|
Price: ₹87.78 (1.84%) | ||
| 52 Week Low: ₹60.00 52 Week High: ₹106.50 |
|||
| Market Capital: 124.34 Crore (Small-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Share Price HistoryBALPHARMA FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bal Pharma Share Price Target For 2026
- 1.1.1: Bal Pharma Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bal Pharma Share Price Target For 2027
- 1.2.1: Bal Pharma Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bal Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Bal Pharma Brief Company Overview
- 4: Bal Pharma Financial Performance
- 4.0.1: Is Bal Pharma A Good Buy For Long Term?
Bal Pharma, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry showing 5.6% quarterly revenue growth with 2.2% profit margin.
To predict the Bal Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bal Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Bal Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bal Pharma shares in 2026, see the table below.
Bal Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 103.82 (+18.27%) | Volatility: ATR T2 |
| 2026 Target 2 | 97.40 (+10.95%) | Volatility: ATR T1 |
| 2026 Target 1 | 94.87 (+8.07%) | Volatility: BB Upper |
| Current Price | 87.78 | Bal Pharma's share price as of 15 Jun 2026 |
| Stop Loss 1 | 86.53 (-1.43%) | Trend: EMA9 |
| Stop Loss 2 | 83.25 (-5.17%) | 50.00% Weekly Fib Retrace |
| Stop Loss 3 | 80.25 (-8.58%) | Trend: SMA50 |
Short-Term Technical Outlook
Current Technical Position: Bal Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹80.25 serves as the nearest technical reference point.
Historical Returns: 3-month: +31.09% | 6-month: +17.86% | 1-year: -16.65%
Bal Pharma Share Price Target For 2027
The line chart displays the monthly closing prices of Bal Pharma with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bal Pharma shares in 2027, see the table below.
Bal Pharma Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 103.82 (+18.27%) | Volatility: ATR T2 |
| 2027 Target 2 | 97.40 (+10.95%) | Volatility: ATR T1 |
| 2027 Target 1 | 94.87 (+8.07%) | Volatility: BB Upper |
| Current Price | 87.78 | Bal Pharma's share price as of 15 Jun 2026 |
| Stop Loss 1 | 86.53 (-1.43%) | Trend: EMA9 |
| Stop Loss 2 | 83.25 (-5.17%) | 50.00% Weekly Fib Retrace |
| Stop Loss 3 | 80.25 (-8.58%) | Trend: SMA50 |
Long-Term Technical Outlook
52-Week Range Analysis: Bal Pharma is currently trading at 59.7% of its 52-week range (₹60 - ₹106.5).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: -16.65% | 3-year: -2.22% | 5-year: -11.24%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bal Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹87.78 | ||
| 2026 | ₹86.95 | -0.94554568238779% | ₹88.25 |
| 2027 | ₹106.66 | +22.668200115009% | ₹108.26 |
| 2028 | ₹113.97 | +6.8535533470842% | ₹115.68 |
| 2029 | ₹125.79 | +10.371150302711% | ₹127.68 |
| 2030 | ₹137.24 | +9.1024723745926% | ₹139.30 |
| 2031 | ₹168.88 | +23.054503060332% | ₹171.41 |
| 2032 | ₹177.07 | +4.8495973472288% | ₹179.73 |
| 2033 | ₹176.87 | -0.11294968091714% | ₹179.52 |
| 2034 | ₹177.48 | +0.344886074518% | ₹180.14 |
| 2035 | ₹177.75 | +0.15212981744422% | ₹180.42 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bal Pharma Brief Company Overview
Bal Pharma: A Reputable Leader in Pharmaceuticals Since its inception in 1987, Bal Pharma Limited has established itself as a trusted name in the pharmaceutical industry. Headquartered in Bengaluru, India, the company has a global presence in India, Uzbekistan,...
Guatemala, and Malta. Product Range: Prescription drugs Generics OTC products Intravenous infusion products Bulk actives Anti-infectives Pain management Respiratory care Women's health products Diabetic care products Herbal/ayurvedic preparations Anti-hypertensive, anti-lipidemic, and anti-obese products Skin care and bone health products Cardiac care products Commitment: Bal Pharma is dedicated to providing high-quality products and services to improve patient health.Bal Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 201.47 Crore | Market valuation of Bal Pharma's shares. |
| Revenue (TTM) | 343.19 Crore | Total revenue generated by Bal Pharma over the past twelve months. |
| Net Income (TTM) | +7.56 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 5.43% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 2.2% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+5.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+207.39% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
201.62 | Company's total debt divided by total shareholder equity. |
| Total Debt | 139.64 Crore | Sum of Bal Pharma's current & long-term financial obligations. |
| Total Cash | 20.04 Crore | Total amount of liquid funds available to Bal Pharma. |
| Beta | 0.55 | Beta is less than 1 indicating that the Bal Pharma's price is less volatile than the market. |
Is Bal Pharma A Good Buy For Long Term?
Bal Pharma, a small-cap stock with a market capitalization of ₹201.47 crore, shows strong growth potential but carries considerable risk. While its 12-month revenue reached ₹343.19 crore and YTD returns are 37.07%, a significant debt of ₹139.64 crore (Q1 2024-25) offsets its ₹20.04 crore cash balance. A low profit margin of 2.2% and substantial year-over-year earnings growth (207.39%) warrant further investigation. Despite impressive past returns, a long-term investment decision requires careful analysis of its debt levels and future profitability to determine if it's a good, average, or not a good buy.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
